14-16 May 2012 the I-MOVE network as well as a number of leading international experts in the field of influenza vaccine effectiveness met in Rome to discuss results of the 2011-12 season and to plan for the next season’s activities.
The study of Wood et al has shown a standard can reduce the inter-laboratory variability of the results and bring coherence to the inter-assay results as well.
Investigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010 - Final Report of National Narcolepsy Study Steering Committee, Department of Health, Ireland
A rapid communication published on April 12th 2012 describes the early results of the annual multicentre case-control study undertaken by the ECDC sponsored I-MOVE consortium whose work is coordinated by an Epiconcept team
Preliminary results of European vaccine effectiveness study show decreased protective effect of the seasonal influenza vaccine in 2011/2012 season. ECDC Director Marc Sprenger calls for action.
In the autumn of 2011 a United States Government body, the NSABB established under the National Institutes of Health considered two scientific papers describing experimental work manipulating avian influenza viruses.
A pair of linked papers from Finland concerning the above topic, one epidemiological and the second combining both clinical and epidemiological were published on March 28th in the open access journal, PLoS One.(1,2).
One of the most important functions and outputs of the laboratory aspect of the Global Influenza Surveillance and Response System (GISRS) coordinated by WHO are biannual influenza vaccine strain selection meetings that take place each year around February and September. These scientific meetings make recommendations on the antigens to go into the influenza vaccines for the northern hemisphere (February meeting) and southern hemisphere seasons (September meeting).